Arcutis Biotherapeutics/$ARQT
1D1W1MYTD1Y5YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
- Ticker
- $ARQT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 354
- Headquarters
- Westlake Village, United States
- Website
- www.arcutis.com
ARQT Metrics
BasicAdvanced
$3.2B
117.68
$0.22
1.53
-
Price and volume
Market cap
$3.2B
Beta
1.53
52-week high
$31.77
52-week low
$15.10
Average daily volume
1.5M
Financial strength
Current ratio
2.917
Quick ratio
2.455
Long term debt to equity
48.593
Total debt to equity
51.744
Interest coverage (TTM)
2.47%
Profitability
EBITDA (TTM)
36.503
Gross margin (TTM)
91.14%
Net profit margin (TTM)
6.15%
Operating margin (TTM)
7.38%
Effective tax rate (TTM)
2.66%
Revenue per employee (TTM)
$1,310,000
Management effectiveness
Return on assets (TTM)
5.09%
Return on equity (TTM)
15.86%
Valuation
Price to earnings (TTM)
117.68
Price to revenue (TTM)
7.045
Price to book
14.43
Price to tangible book (TTM)
15.39
Price to free cash flow (TTM)
83.493
Free cash flow yield (TTM)
1.20%
Free cash flow per share (TTM)
0.304
Growth
Revenue change (TTM)
76.11%
Earnings per share change (TTM)
-129.00%
3-year revenue growth (CAGR)
241.43%
3-year earnings per share growth (CAGR)
-66.03%
What the Analysts think about ARQT
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
ARQT Financial Performance
Revenues and expenses
ARQT Earnings Performance
Company profitability
ARQT News
AllArticlesVideos
Arcutis Biotherapeutics Q2 Earnings Call Highlights
MarketBeat2 weeks ago
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment
Investors Business Daily1 month ago
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
MarketBeat2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.